Welcome to our dedicated page for Turn Therapeutics SEC filings (Ticker: TTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. While no specific filings are listed in the provided data, Turn’s public communications reference its status as a Nasdaq-listed company and describe a direct listing structure used to enter the public markets.
For a company like Turn Therapeutics, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on clinical programs such as GX-03 for moderate to severe atopic dermatitis, late-stage efforts in onychomycosis, and vaccine initiatives based on its PermaFusion delivery platform. These reports often include discussions of research and development spending, risk factors related to clinical trials and regulatory pathways, and descriptions of commercial agreements, such as the global supply, development, and license agreement with Medline.
Other important SEC documents for a Nasdaq-listed biotechnology company can include current reports on Form 8-K, which may disclose material events like new strategic partnerships, changes to the Board of Directors, or significant financing arrangements. Filings related to equity financing structures, such as the GEM Global Yield agreement and share purchase agreements referenced in company updates, are also commonly detailed in SEC submissions.
On Stock Titan, Turn Therapeutics filings are supplemented with AI-powered summaries designed to explain key sections of lengthy documents in clear language. These tools can help users quickly understand complex topics such as clinical development disclosures, collaboration terms, and capital strategy without reading every page. As new TTRX filings are made available through EDGAR, this page can serve as a starting point for reviewing the company’s regulatory and financial reporting history.
Turn Therapeutics Inc. reports a Schedule 13G showing Bradley Burnam holds 15,716,260 shares of common stock, representing 52.76% of the class. The filing states these shares include options exercisable within 60 days and are held by BEB Holdings, LLC, of which Burnam is sole member. The company reported 29,788,040 shares outstanding as of March 30, 2026.
Turn Therapeutics Inc. director and Chief Executive Officer Burnam Bradley Evan reported a bona fide gift of 300,000 shares of common stock, carried out through BEB Holdings, LLC, an entity he solely controls. The gift involved no sale proceeds, with a reported price of $0.00 per share. Following this indirect disposition, BEB Holdings, LLC, which is deemed beneficially owned by Burnam Bradley Evan due to his sole voting and dispositive power, held 15,716,260 shares of Turn Therapeutics common stock.
Turn Therapeutics Inc. director Arthur F. Golden reported a bona fide gift of 300,000 shares of Common Stock. The shares were transferred at a reported price of $0.0000 per share, reflecting a non-market, no‑consideration disposition. Following the gift, he directly holds 360,602 Common Stock shares.
Turn Therapeutics Inc. reported that Chief Executive Officer and director Burnam Bradley Evan received an employee stock option grant covering 160,000 shares of common stock at an exercise price of $3.43 per share. The option was granted as compensation at no purchase price on the grant date.
According to the vesting terms, 25% of the option will vest on the first anniversary of the grant date, with the remaining 75% vesting in equal installments over the following 36 months, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan.
Turn Therapeutics Inc. reported that officer Zuraiz Chaudhary received an award of 80,000 employee stock options on April 1, 2026. These options allow the purchase of common stock at an exercise price of $3.12 per share, with no cash paid at grant.
After this award, Chaudhary holds 80,000 stock options directly. The options vest over time: 25% vests on the first anniversary of the grant date and the remaining 75% vests ratably over the following 36 months, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. This is a compensation grant, not an open‑market share purchase or sale.
Turn Therapeutics Inc. files Post-Effective Amendment No. 1 to a Form S-1 registering up to 7,000,000 shares of its common stock for resale by GEM affiliates. The prospectus covers (i) shares issuable to GEM under a committed equity purchase agreement with an $85.0 million aggregate limit, (ii) 161,905 Commitment Fee Shares previously issued (formula-based), and (iii) a 1,192,207-share warrant issued at an exercise price of $5.03 per share. The company states it will not receive proceeds from sales by the selling stockholders under this registration, although it may receive proceeds if it elects to sell shares to GEM under the GEM Purchase Agreement (subject to registration and conditions). The prospectus notes Nasdaq listing symbol TTRX and a March 30, 2026 closing price of $3.22 per share.
Turn Therapeutics Inc. filed a Post-Effective Amendment registering 17,868,760 shares of common stock for resale by certain stockholders. The resale prospectus covers sales "from time to time" by the Registered Stockholders; the company will receive no proceeds from those resale transactions. The prospectus incorporates recent Exchange Act reports and notes the company is an emerging growth, smaller reporting and controlled company. It also discloses a March 30, 2026 closing stock price of $3.22 and 29,445,183 shares outstanding as of December 31, 2025.
Turn Therapeutics Inc. files its annual report describing a dermatology-focused pipeline built around GX-03, a non-systemic topical immunomodulator for moderate-to-severe eczema and onychomycosis, plus an exploratory thermostable intranasal vaccine platform.
The company leverages prior 510(k) device clearances and animal data to run an approximately 114–120 patient randomized, double-blind, vehicle-controlled Phase 2-equivalent eczema trial, with interim analysis at 50% enrollment and topline results expected mid-2026. GX-03 has shown preclinical cytokine inhibition and antifungal nail penetration with favorable tolerability. Turn pursues a capital-light model using contract manufacturers and partners, highlighted by a MiMedx license for the collagen-based FleX Product with up to $69.55 million in potential milestones plus mid-single-digit royalties, and an October 2025 Medline agreement to co-develop and distribute PermaFusion-based wound and personal care products globally.
The report also discloses net losses, an accumulated deficit, and substantial doubt about the company’s ability to continue as a going concern, alongside reliance on external financing, including an up to $85.0 million share purchase facility with GEM and potential future equity dilution.
Turn Therapeutics Inc. reported full year 2025 results and provided clinical and corporate updates. Operating expenses rose to $5.9 million, driven mainly by general and administrative costs, leading to a net loss of $3.2 million compared with $1.8 million in 2024. Other income of $2.7 million, including gains from changes in fair value of a derivative liability instrument and a forward contract liability, partially offset operating losses. Cash and cash equivalents increased to $5.1 million and total assets to $12.2 million, with stockholders’ equity turning positive.
The company highlighted its Phase 2 trial of lead candidate GX-03 for moderate-to-severe atopic dermatitis, with topline results expected in mid-2026. Turn also secured up to $25 million in growth capital from Avenue Capital Group, which it states is expected to extend its runway through the end of 2027, and referenced a global license, supply, and distribution agreement with Medline that it believes could enable revenue beginning in late 2026.